Properties |
Information |
PhytoCAT-ID |
PhytoCAT-2190 |
Phytochemical name or plant extracts |
Forskolin |
PMID |
29574069 |
Literature evidence |
Recently, forskolin is emerging as a possible novel molecule for cancer therapy. |
IUPAC name |
[(3R,4aR,5S,6S,6aS,10S,10aR,10bS)-3-ethenyl-6,10,10b-trihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-5,6,6a,8,9,10-hexahydro-2H-benzo[f]chromen-5-yl] acetate |
Phytochemicals’ class or type of plant extracts |
Labdane diterpenoid |
Source of phytochemicals or plant Extracts |
Coleus barbatus |
|
Geographical availability |
Burundi, China South-Central, East Himalaya, Eritrea, Ethiopia, India, Kenya, Nepal, Oman, Rwanda, Saudi Arabia, Somalia, Sri Lanka, Sudan, Tanzania, Thailand, Uganda, West Himalaya, Yemen, Zaïre |
Plant parts |
NA |
Other cancers |
Breast cancer, Cervical cancer |
Target gene or protein |
ERK1/2 |
Gene or Protein evidence |
Forskolin improves sensitivity to doxorubicin of triple negative breast cancer cells via Protein Kinase A-mediated ERK1/2 inhibition |
Target pathways |
NA |
IC50 |
NA |
Potency |
Our findings sustain the evidence of anticancer activity mediated by forskolin and encourage the design of future in-vivo/clinical studies in order to explore forskolin as a doxorubicin sensitizer for possible use in TNBC patients. |
Cell line/ mice model |
MDA-MB-231, MDA-MB-468, MCF7, HeLa |
Additional information |
It is important to note that the forskolin-induced potentiation of sensitivity to doxorubicin is accompanied by a strong inhibition of ERK1/2 phosphorylation, is mimicked by ERK inhibitor PD98059 and is prevented by pre-treatment with Protein Kinase A (PKA) and adenylate cyclase inhibitors.
Altogether, our data indicate that forskolin sensitizes TNBC cells to doxorubicin via a mechanism depending on the cAMP/PKA-mediated ERK inhibition. |
PubChem ID |
47936 |
Additional PMIDs |
24593874 |
Additional sources of information |
https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:60454692-2 |
Safety |
NA |